Active Surveillance of Very-low-risk Prostate Cancer in the Setting of Active Treatment of Benign Prostatic Hyperplasia With 5α-reductase Inhibitors


      To review the efficacy of treating benign prostatic hyperplasia and very-low-risk prostate cancer (PCa) in patients receiving active surveillance and 5α-reductase inhibitor (5-ARI; finasteride or dutasteride) treatment.

      Materials and Methods

      Eighty-two men with very-low-risk PCa (clinical stage T1c, Gleason score ≤6, <3 biopsy cores positive with ≤50% involvement, and prostate-specific antigen density ≤0.15 ng/mL/g) and benign prostatic hyperplasia (≥30 cm3) received active surveillance and were treated with a 5-ARI.


      All 82 men completed 1 year of 5-ARI therapy (n = 79) or underwent early biopsy for cause (n = 3). Restaging biopsies were performed for 76 men (22 underwent a second restaging biopsy and 1 a third restaging biopsy), 4 patients were awaiting biopsy, and 2 were lost to follow-up before the first restaging biopsy. At the first restaging biopsy, of the 76 men, 41 (54%) had no PCa, 16 (21%) continued to have very-low-risk PCa, 15 (20%) had progressed to low-risk PCa (>2 cores positive and Gleason score ≤6), and 4 (5%) had progressed to intermediate-risk PCa (Gleason score 7). Of the 76 biopsies, 20 were performed early for cause, with 11 (55%) showing PCa progression. Of the 82 patients, 22 (27%) underwent treatment of PCa.


      Active surveillance of very-low-risk PCa in the setting of 5-ARI therapy for benign prostatic hyperplasia appears to be a safe therapeutic option, because most (57 of 82; 70%) patients maintained very-low-risk PCa or had negative follow-up biopsies during a 3-year follow-up period. Complementary to the Prostate Cancer Prevention Trial, our results indicate that 5-ARI therapy increases prostate-specific antigen sensitivity and can aid the clinician in appropriately targeting biopsies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Andriole G.L.
        Overview of pivotal studies for prostate cancer risk reduction, past and present.
        Urol. 2009; 73: 36-43
        • Seigel R.
        • Ward E.
        • Brawley O.
        • et al.
        Cancer statistics, 2011.
        CA Cancer J Clin. 2011; 61: 212-236
      1. National Comprehensive Cancer Network. NCCN Prostate Cancer Guidelines. 2011.

        • Thorpe A.
        • Neal D.
        Benign prostatic hyperplasia.
        Lancet. 2003; 361: 1359-1367
        • Andriole G.L.
        • Roehrborn C.
        • Schulman C.
        • et al.
        Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
        J Urol. 2004; 64: 537-543
        • Cohen Y.C.
        • Liu K.S.
        • Heyden N.L.
        • et al.
        Due to the effect of finasteride on prostate volume: a modeling approach for analysis of the prostate cancer prevention trial.
        J Natl Cancer Inst. 2007; 99: 1366-1374
        • Thompson I.M.
        • Ankerst D.P.
        • Chi C.
        • et al.
        Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
        J Clin Oncol. 2007; 25: 3076-3081
        • Klein E.A.
        • Tangen C.M.
        • Goodman P.J.
        • et al.
        Assessing benefit and risk in the prevention of prostate cancer: the Prostate Cancer Prevention Trial revisited.
        J Clin Oncol. 2005; 23: 7460-7466
        • Roehrborn C.G.
        • Nickel J.C.
        • Andriole G.L.
        • et al.
        Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the Reduction by Dutasteride of Prostate Cancer Events trial.
        J Urol. 2011; 78: 641-647
        • Finelli A.
        • Trottier G.
        • Lawrentschuk N.
        • et al.
        Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer.
        Eur Urol. 2011; 59: 509-514
        • Fleshner N.E.
        • Lucia M.S.
        • Egerdie B.
        • et al.
        Dutasteride in localized prostate cancer management: the REDEEM randomized, double-blind, placebo-controlled trial.
        Lancet. 2012; 379: 1103-1111
        • Thompson I.M.
        • Chi C.
        • Ankerst D.P.
        • et al.
        Effect of dutasteride on the sensitivity of PSA for detecting prostate cancer.
        J Natl Cancer Inst. 2006; 98: 1128-1133
        • Merrick G.S.
        • Wallner K.E.
        • Butler W.M.
        Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland.
        J Urol. 2003; 169: 1643-1652
        • Levy D.A.
        • Jones J.S.
        Impact of prostate gland volume on cryoablation prostate-specific antigen outcomes.
        Urology. 2011; 77: 994-998
        • Meyer J.P.
        • Bell C.R.W.
        • Elwell C.
        • et al.
        Brachytherapy for prostate cancer: is the pretreatment prostate volume important?.
        BJU Int. 2008; 102: 1586-1588
        • Sanda M.G.
        • Dunn R.L.
        • Michalski J.
        • et al.
        Quality of life and satisfaction with outcome among prostate-cancer survivors.
        N Engl J Med. 2008; 358: 1250-1261
        • Shahinian V.B.
        Androgen deprivation for prostate cancer: the case for “first, do no harm.”.
        Cancer. 2012; 118: 3232-3235

      Linked Article

      • Editorial Comment
        UrologyVol. 81Issue 5
        • Preview
          The use of 5-ARIs in men undergoing active surveillance for low-risk PCa has been controversial. This study adds data that 5-ARI therapy could be beneficial. The results are consistent with those from the REDEEM trial in that a significant majority (75%) of men receiving 5-ARI had no evidence of pathologic cancer progression at the restaging biopsy after a median follow-up of 35 months.
        • Full-Text
        • PDF